| Methods |
4‐week placebo run‐in; inclusion criteria= not reported but baseline DBP for all groups is at least 90 mm Hg; 12‐week total double‐blind treatment; increasing doses of enalapril 10, 20, and 40 mg daily every 4 weeks |
| Participants |
All patients: n= 34(33 male,1 female) white patients;
Enalapril once and twice daily: n=21; mean age=52(11) years; baseline SBP=143(15) mm Hg, DBP=93(5) mm Hg;
Placebo: n=12; mean age=50(17) years; baseline SBP=150(14) mm Hg, DBP=92(7) mm Hg |
| Interventions |
Enalapril 10 mg once daily;
Enalapril 10 mg twice daily;
Placebo;
first dose taken in the morning |
| Outcomes |
Trough sitting SBP/DBP |
| Notes |
Used week 4 DBP only since patients treated with enalapril 10 mg once daily did not have SBP >/= 140mm Hg at baseline; BP change and SD of change not reported; endpoint BP reported; endpoint SD not reported; imputed overall trial mean SD of change; BP data from Figure 1, p. 461; BP measurement device not reported; Jadad score=2; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
